Trial reportRevista peruana de medicina experimental y salud publica2026
Feasibility and preliminary biomarker responses to capsules containing green coffee extract enriched with magnesium di-malate in women with type 2 diabetes mellitus: a randomized, placebo-controlled pilot trial.
Trial report in Revista peruana de medicina experimental y salud publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objectives: To evaluate the feasibility of a 12-week, randomized, double-blind, placebo-controlled intervention with capsules containing green coffee extract enriched with magnesium di-malate in women with type 2 diabetes mellitus, including overall adherence to capsule use and tolerability, as well as to explore preliminary between-group differences in glycemic and cardiovascular biomarkers. Materials and methods: This randomized, double-blind, placebo-controlled pilot trial included 48 eligible women with type 2 diabetes mellitus, equally assigned to the placebo group (n=24) or the experimental group (n=24). Participants received capsules daily for 12 weeks and were followed up through nursing consultations. Overall retention was 83.3% (40/48), and overall adherence to capsule use was estimated at over 82%. Glycemic biomarkers included fasting glucose, estimated mean glucose, HbA1c, insulin, HOMA-IR, and HOMA-β. Cardiovascular biomarkers included urea, creatinine, uric acid, apolipoprotein B, triglycerides, and the triglycerides-glucose index. Data were analyzed based on avail-able data from participants who completed follow-up and the final evaluation. Results: The protocol was feasible under the study conditions, although retention differed between groups. Glycemic biomarkers varied during follow-up in both groups, without conclusive evidence of a consistent between-group effect. In the experimental group, triglycerides and the triglycerides-glucose index showed numerical reductions, while uric acid fluctuated in both groups. These findings should be interpreted as exploratory. Conclusions: This pilot trial provided preliminary information on the feasibility of implementing this intervention in women with type 2 diabetes mellitus. The biomarker findings were exploratory and imprecise and do not allow for definitive conclusions on efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.